Scarica l'app Stockscreener
0.1114
37.27%
-0.0662
Pre-mercato:
.11
-0.0014
-1.26%
Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie
Price to earnings ratio of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Total revenue of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Sangamo Therapeutics, Inc. Cash Flow – OTC:SGMO - TradingView
Enterprise value to EBITDA ratio of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Net debt of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Cost of goods sold of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Sangamo Therapeutics, Inc. Balance Sheet – OTC:SGMO - TradingView
Operating income of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Sangamo Therapeutics, Inc. Revenue Breakdown – OTC:SGMO - TradingView
Net current asset value per share of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Long term debt to total equity ratio of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
EBIT per share of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
EBITDA margin % of Sangamo Therapeutics, Inc. – OTC:SGMO - TradingView
Sangamo Therapeutics, Inc. Income Statement – OTC:SGMO - TradingView
Sangamo Therapeutics, Inc. Earnings and Revenue – OTC:SGMO - TradingView
Sangamo Stock Jumps Before Nasdaq Exit: Why SGMO Investors Are Watching May 5 - TechStock²
Sangamo Therapeutics (SGMO) to Release Earnings on Monday - MarketBeat
Sangamo Therapeutics | 10-K/A: Annual report (Amendment) - Moomoo
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Short Interest Update - MarketBeat
SGMO Forecast, Price Target & Analyst Ratings | SANGAMO THERAPEUTICS INC (NASDAQ:SGMO) - ChartMill
MSN Money - MSN
Sangamo Therapeutics 2025 Executive Compensation, Stock Awards, and Corporate Objectives Overview - Minichart
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT) - The Manila Times
SGMO Financials: Income Statement, Balance Sheet & Cash Flow | Sangamo Therapeutics Inc - Stock Titan
H.C. Wainwright Reaffirms Their Buy Rating on Sangamo Therapeutics (SGMO) - The Globe and Mail
SANGAMO THERAPEUTICS, INC. (SGMO) - MSN
Sangamo stock leaves Nasdaq May 5 but keeps SGMO ticker on OTCQB - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Sangamo Therapeutics to be delisted from Nasdaq, trading to move to OTCQB - Investing.com Nigeria
Sangamo Therapeutics (SGMO) Nasdaq delisting shifts stock to OTCQB market - Yahoo Finance
Sangamo Therapeutics, Inc. Files Form 8-K with SEC – Key Company and Stock Information (April 2026) - Minichart
Sangamo Therapeutics | 8-K: Current report - Moomoo
Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market - The Manila Times
Sangamo Therapeutics To Transition Common Stock To Otcqb Venture Market On May 5, 2026 - TradingView
Crude Oil Jumps 5%; Automatic Data Processing Posts Upbeat Earnings - Sahm
Q2 2025 Sangamo Therapeutics Inc Earnings Call Transcript - GuruFocus
Q1 2025 Sangamo Therapeutics Inc Earnings Call Transcript - GuruFocus
Q3 2025 Sangamo Therapeutics Inc Earnings Call Transcript - GuruFocus
Gregory Davis Sells 69,827 Shares of Sangamo Therapeutics (NASDAQ:SGMO) Stock - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) SVP Sells $89,944.92 in Stock - MarketBeat
Sangamo Therapeutics SVP sells $89,183 in common stock - Investing.com
Sangamo Therapeutics’ head of research & technology sells $17,694 in stock - Investing.com
Sangamo Therapeutics (SGMO) Stock Fundamentals | Sangamo Therapeutics Inc. misses EPS ests by 79.7%Stock Trading Network - UBND thành phố Hải Phòng
Sangamo targets summer 2026 for Fabry BLA submission while advancing neurology pipeline and partner talks - MSN
Sangamo Therapeutics prices $23M securities offering - MSN
SGMO ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Sangamo Therapeutics, Inc. Shareholders Who Lost Money - ACCESS Newswire
Sangamo Therapeutics (NASDAQ:SGMO) Lowered to Strong Sell Rating by Zacks Research - MarketBeat
SGMO News | SANGAMO THERAPEUTICS INC (NASDAQ:SGMO) - ChartMill
Fabry Disease Market Set for Robust Growth by 2034, Driven by Gene Therapy Breakthroughs and Expanding Pipeline from Sangamo, Sanofi, Amicus & Emerging Innovators | DelveInsight - Barchart.com
HC Wainwright Has Negative Forecast for SGMO FY2026 Earnings - MarketBeat
Analyst Calls: Will Sangamo Therapeutics Inc benefit from geopolitical trendsPortfolio Risk Summary & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Should I Hold Sangamo Therapeutics (SGMO) Stock Now | Price at $0.30, Up 1.13%Top Trending Breakouts - Cổng thông tin điện tử tỉnh Tây Ninh
SGMO SEC FilingsSangamo Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Sangamo (NASDAQ: SGMO) awards 225,000 stock options to accounting chief - Stock Titan
Sangamo (SGMO) CEO Sandy Macrae receives 2.5M stock option grant at $0.2601 - Stock Titan
Sangamo (NASDAQ: SGMO) CLO awarded 800,000 options at $0.2601 - Stock Titan
Equities Analysts Issue Forecasts for SGMO FY2028 Earnings - MarketBeat
Sangamo Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SGMO) 2026-04-02 - Seeking Alpha
Sangamo Therapeutics Faces Rising Trade Policy Risks, Higher Costs and Global Growth Uncertainty - TipRanks
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):